@drjoshaxe's Japan hormone therapy claims, fact-checked

What did @drjoshaxe actually say?

The video features Dr. Mindy Pelz claiming that "only 4% of women in Japan take hormone replacement therapy" while "over 50% of women here in the US are taking hormone therapy." She argues this gap is explained by three lifestyle factors: phytoestrogens in the Japanese diet (primarily from soy), higher physical activity among Japanese seniors, and cultural attitudes that respect older women rather than marginalizing them. She also pushes back on the idea that soy causes breast cancer, calling it "misinformation."

The framing is that American women are medicating a problem that Japanese women are living through naturally, and that lifestyle changes could close that gap. It's a tidy narrative. The question is whether the data supports it.

Does the science back this up?

The HRT usage statistics are real but the explanation is almost certainly oversimplified. The phytoestrogen hypothesis has real research behind it, but the evidence is far weaker than Pelz implies.

First, the numbers. HRT uptake in Japan is genuinely low, with some estimates around 1-5%, though the exact figure shifts by year and survey method. U.S. rates have fluctuated significantly since the 2002 Women's Health Initiative findings caused a dramatic drop; the "over 50%" figure appears to reflect a recent resurgence and may include all hormone therapies, not just traditional HRT. That framing deserves scrutiny.

On phytoestrogens: Japanese women do consume significantly more isoflavones, primarily from soy and fermented soy products like miso and natto. A 2001 study by Nagata et al. in the American Journal of Epidemiology found that higher soy intake correlated with fewer self-reported hot flashes. But a 2007 Cochrane review (Lethaby et al.) found that phytoestrogen supplements produced only modest reductions in hot flash frequency compared to placebo, with no benefit for other menopause symptoms. The jump from dietary soy to "explains Japan's HRT gap" is a significant leap.

On soy and breast cancer: Pelz is largely correct that the fear is overblown in Western wellness culture. Meta-analyses including one by Chen et al. (2014, PLOS ONE) found no increased breast cancer risk from dietary soy in Western women, and some protective association in Asian women. The mechanism differs from synthetic estrogens. She gets credit here.

What did they get wrong (or right)?

The soy-cancer claim is the strongest point in this video. The panic over dietary soy causing breast cancer is not well-supported by current evidence, and Pelz is right to push back on it.

Where this falls apart is the cultural comparison. Japan's low HRT usage isn't simply a lifestyle success story. It reflects a healthcare system historically slow to approve and promote hormone therapy, significant physician reluctance, and a cultural stigma around menopause that made women less likely to seek or report symptoms, not necessarily less likely to experience them. Research by Lock (1993, "Encounters with Aging," University of California Press) documented that Japanese women reported fewer hot flashes, but later work raised questions about whether this reflected reporting differences, dietary factors, or both. Attributing Japan's HRT rate primarily to phytoestrogens and walking is a confident answer to a genuinely complicated question.

The claim that "over 50% of women" in the U.S. currently take HRT also needs sourcing. Post-WHI, U.S. HRT use dropped to roughly 4-5% by some estimates. Recent upticks are real, but 50% is a dramatic number without a clear citation.

What should you actually know?

If you're approaching menopause or already in it, here is what the actual evidence supports. Lifestyle factors including diet, exercise, and sleep do influence menopause symptom severity. That part is not wrong. A 2014 study by Sternfeld et al. in Menopause found that exercise and behavioral interventions meaningfully reduced hot flash burden.

Phytoestrogens from whole food sources like edamame, tofu, and miso appear safe and may offer modest symptom relief for some women. They are not a replacement for HRT in women with significant symptoms, and they have not been shown to deliver the same outcomes as estrogen therapy for bone density or cardiovascular protection in the menopause window.

HRT, when appropriately indicated and started within 10 years of menopause or before age 60, has a strong evidence base for symptom relief and may reduce cardiovascular and bone fracture risk. The decision is individual and should involve a clinician who knows your history, not a viral video. The lifestyle-versus-medicine framing sets up a false choice that ultimately does not serve women well.